Key Metrics
Factor Lens
Seasonal Performance
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
Biogen Inc. is a global biotechnology company that discovers, develops, manufactures and delivers therapies for patients worldwide. The Company operates through two reportable… segments: Neurology and Immunology and Rare Disease. The Neurology segment includes multiple sclerosis (MS) therapies and other neurological products. The Immunology and Rare Disease segment includes therapies for various autoimmune conditions and rare diseases. The Company's product portfolio includes: SPINRAZA for spinal muscular atrophy, SKYCLARYS and QALSODY for rare diseases, ZURZUVAE for depression, VUMERITY and TECFIDERA for MS, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA for MS, and LEQEMBI for Alzheimer's disease (through a collaboration). OCREVUS is a key immunology product. The Company also maintains biosimilar products and engages in contract manufacturing and royalty arrangements. Biogen actively advances a clinical pipeline with programs in neurology, immunology, and rare disease, including Phase 3 trials for multiple candidates. The Company has made strategic acquisitions and collaborations to expand its portfolio, including Reata Pharmaceuticals, Human Immunology Biosciences, and partnerships with organizations like Stoke Therapeutics, City Therapeutics, Eisai, and Ionis Pharmaceuticals for co-development and commercialization of various therapies.
- Name
- Biogen Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher A. Viehbacher · President and Chief Executive Officer
- Employees
- 7,400 as of 2025-12-31
- IPO Date
- 2014-05-20
- Phone
- 6176792000
- Address
- 225 Binney Street, Cambridge, MA 02142
- Website
- http://www.biogenidec.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Stephen A. Sherwin | Director | — |
| Eric K. Rowinsky | Director | — |
| William A. Hawkins | Director | — |
| Maria C. Freire | Chair of the Board | — |
| Christopher A. Viehbacher | President and Chief Executive Officer | — |
Latest News
- 2026-04-26
- 2026-04-24
-
2026-04-24
Biogen Inc. $BIIB Shares Bought by Caprock Group LLC defenseworld.net
-
2026-04-24
Biogen Inc. $BIIB Shares Bought by B. Metzler seel. Sohn & Co. AG defenseworld.net
-
2026-04-22
Biogen upgraded by UBS on ‘slew of pipeline catalysts' going into 2027 proactiveinvestors.com
- 2026-04-22
- 2026-04-22
- 2026-04-21